Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

This early-phase study is testing a new type of immune cell therapy called Allo-RevCAR01-T-CD123 in people with a type of blood cancer called AML (acute myeloid leukemia) that has returned or stopped responding to other treatments. The therapy uses specially engineered immune cells from a donor to attack cancer cells. **You may be eligible if...** - You are 18 or older and weigh at least 45 kg - You have been diagnosed with AML that has a protein called CD123 on the cancer cells - Your cancer has stopped responding to standard treatments or you cannot tolerate them - You have not had an allogeneic (donor) stem cell transplant in the last 2 months - Your heart, liver, and kidneys are functioning adequately - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have a specific type of AML called acute promyelocytic leukemia (APL) - You have had a stroke, seizure, or brain bleed in the past 12 months - You have Parkinson's disease or active epilepsy - You are HIV positive or have active hepatitis B or C - You have an active serious infection or active autoimmune disease requiring immunosuppression - You have had prior gene-modified cell therapy Talk to your doctor to see if this trial is right for you.